Randomised clinical trial: a 1‐week, double‐blind, placebo‐controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 <scp>MMS</scp>) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1‐year open‐label extension

Abstract

This study demonstrates superior efficacy of pancreatin 25 000 over placebo in patients with PEI after pancreatic surgery, measured by change in CFA. Pancreatin was generally well tolerated at the high dose administered (EudraCT registration number: 2005-004854-29).